230 related articles for article (PubMed ID: 26373844)
1. Identifying therapeutic targets in gastric cancer: the current status and future direction.
Yu B; Xie J
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):90-6. PubMed ID: 26373844
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
3. GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer.
Yu B; Gu D; Zhang X; Li J; Liu B; Xie J
Oncotarget; 2017 Apr; 8(16):27412-27427. PubMed ID: 28404967
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.
Oh SC; Sohn BH; Cheong JH; Kim SB; Lee JE; Park KC; Lee SH; Park JL; Park YY; Lee HS; Jang HJ; Park ES; Kim SC; Heo J; Chu IS; Jang YJ; Mok YJ; Jung W; Kim BH; Kim A; Cho JY; Lim JY; Hayashi Y; Song S; Elimova E; Estralla JS; Lee JH; Bhutani MS; Lu Y; Liu W; Lee J; Kang WK; Kim S; Noh SH; Mills GB; Kim SY; Ajani JA; Lee JS
Nat Commun; 2018 May; 9(1):1777. PubMed ID: 29725014
[TBL] [Abstract][Full Text] [Related]
5. New agents on the horizon in gastric cancer.
Lordick F; Shitara K; Janjigian YY
Ann Oncol; 2017 Aug; 28(8):1767-1775. PubMed ID: 28184417
[TBL] [Abstract][Full Text] [Related]
6. Hedgehog signaling pathway as a potential target in the treatment of advanced gastric cancer.
Lee DH; Lee SY; Oh SC
Tumour Biol; 2017 Jun; 39(6):1010428317692266. PubMed ID: 28621241
[TBL] [Abstract][Full Text] [Related]
7. Neferine inhibits growth and migration of gastrointestinal stromal tumor cell line GIST-T1 by up-regulation of miR-449a.
Xue F; Liu Z; Xu J; Xu X; Chen X; Tian F
Biomed Pharmacother; 2019 Jan; 109():1951-1959. PubMed ID: 30551450
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives.
Papaetis GS; Syrigos KN
Cancer Metastasis Rev; 2010 Mar; 29(1):151-70. PubMed ID: 20112054
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment.
Li K; Dan Z; Nie YQ
World J Gastroenterol; 2014 May; 20(18):5420-6. PubMed ID: 24833872
[TBL] [Abstract][Full Text] [Related]
11. Identifying and targeting cancer stem cells in the treatment of gastric cancer.
Bekaii-Saab T; El-Rayes B
Cancer; 2017 Apr; 123(8):1303-1312. PubMed ID: 28117883
[TBL] [Abstract][Full Text] [Related]
12. Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche.
Hayakawa Y; Ariyama H; Stancikova J; Sakitani K; Asfaha S; Renz BW; Dubeykovskaya ZA; Shibata W; Wang H; Westphalen CB; Chen X; Takemoto Y; Kim W; Khurana SS; Tailor Y; Nagar K; Tomita H; Hara A; Sepulveda AR; Setlik W; Gershon MD; Saha S; Ding L; Shen Z; Fox JG; Friedman RA; Konieczny SF; Worthley DL; Korinek V; Wang TC
Cancer Cell; 2015 Dec; 28(6):800-814. PubMed ID: 26585400
[TBL] [Abstract][Full Text] [Related]
13. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
14. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
15. The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.
Wang Z; Wang Q; Xu G; Meng N; Huang X; Jiang Z; Chen C; Zhang Y; Chen J; Li A; Li N; Zou X; Zhou J; Ding Q; Wang S
RNA Biol; 2020 Nov; 17(11):1576-1589. PubMed ID: 31885317
[TBL] [Abstract][Full Text] [Related]
16. PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells.
Cai W; Chen G; Luo Q; Liu J; Guo X; Zhang T; Ma F; Yuan L; Li B; Cai J
Mol Cancer Ther; 2017 Jun; 16(6):1187-1198. PubMed ID: 28336807
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of human adipose stem cells in a cancer stem cell-like gastric cancer cell model.
Liu G; Neumeister M; Reichensperger J; Yang RD
Int J Oncol; 2013 Oct; 43(4):1301-9. PubMed ID: 23900519
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of miR-10 family in gastric cancer.
Liu F; Shi Y; Liu Z; Li Z; Xu W
Cell Cycle; 2021 Aug; 20(15):1468-1476. PubMed ID: 34229543
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
20. hsa_circ_0000520 influences herceptin resistance in gastric cancer cells through PI3K-Akt signaling pathway.
Lv X; Li P; Wang J; Gao H; Hei Y; Zhang J; Li S
J Clin Lab Anal; 2020 Oct; 34(10):e23449. PubMed ID: 32701211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
